Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: endo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2022 | $3.00 → $1.00 | Neutral → Underweight | Piper Sandler |
| 3/9/2022 | $11.00 → $6.00 | Buy | Citigroup |
| 3/2/2022 | $5.00 → $3.00 | Neutral | Piper Sandler |
| 3/2/2022 | $5.00 → $2.00 | Equal-Weight → Underweight | Barclays |
| 12/16/2021 | $7.00 → $5.00 | Equal-Weight | Barclays |
| 8/31/2021 | $10.00 → $3.00 | Overweight → Neutral | Piper Sandler |
| 8/9/2021 | $6.00 → $5.00 | Sector Perform | RBC Capital |
DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer. "As we manage thro
DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durabl
DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from May 6, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on May
DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance. "Endo's solid operational and financial performance in the fourth-quarter ended a year of strong performance across all of our business segments," said Blaise Coleman, President and Chief Executive Officer at Endo. "As we look forward to 2022 and begin to transition through the VASOSTRICT® loss of exclusivity and the ongoing COVID-19 driven market conditions
DUBLIN, Jan. 25, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its fourth–quarter and full-year 2021 financial results on February 28, 2022 and members of its senior management team will host a conference call and webcast on March 1, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 4272796. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from March 1, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on March 8, 2022 by dialing U.S./Canada (855) 859-2056 International (404) 537-3406, and entering t
DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the third-quarter ended September 30, 2021. "We delivered strong third-quarter results driven by outstanding execution across all of our businesses. As a result of our year-to-date performance and our expectations for the remainder of 2021, we are raising our full-year 2021 financial guidance," said Blaise Coleman, President and Chief Executive Officer at Endo. "Additionally, we are pleased with our progress against our strategic priorities including our efforts to ex
DUBLIN, Aug. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the second-quarter ended June 30, 2021. "Our second-quarter 2021 results reflect strong sequential growth in our Branded Pharmaceuticals segment driven by XIAFLEX®, and better than expected performance of our Sterile Injectables and Generic Pharmaceuticals segments," said Blaise Coleman, President and Chief Executive Officer at Endo. "Moving forward, we remain committed to further advancing our strategic priorities by delivering on our business transformation initiatives and investing in the on-going launch of QWO®, the growth of XIAFLEX® and the progression of our product pipeline.
DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired). "We're pleased to have completed the acquisition of BioSpecifics, which immediately enhances our adjusted EBITDA and the profitability profile of both XIAFLEX® and Qwo™—two of our most durable and differentiated products with significant long-term growth potential," said Blaise Coleman, President and
DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. "Dr. Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. "His broad therapeutic expertis
DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board. Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Continue Reading Jennifer M. Chao Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. She is the founder
Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Kn
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
SC 13G/A - Endo International plc (0001593034) (Subject)
SC 13G/A - Endo International plc (0001593034) (Subject)
SC 13G/A - Endo International plc (0001593034) (Subject)
SC 13G/A - Endo International plc (0001593034) (Subject)
SC 13G - Endo International plc (0001593034) (Subject)
MONTREAL, June 12, 2023 /CNW/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sensitivit
MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sen
Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebted
SK Biopharmaceuticals is eligible to receive milestones for future approval and commercialization in Canada and Israel PANGYO, South Korea, Aug. 9, 2022 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd. announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. If Health Canada approves this NDS, Paladin Labs would be able to launch cenobamate in Canada. In December
DUBLIN, Aug. 9, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the second-quarter ended June 30, 2022. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 Change 2022 2021 Change Total Revenues, Net $ 569,114 $ 713,830 (20) % $ 1,221,373 $ 1,431,749 (15) % Reported (Loss) Income from Continuing Operations $ (1,880,883) $ (10,184) NM $ (1,946,183) $ 36,875 NM Reported Diluted Weighted Avera
MONTREAL, Aug. 8, 2022 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), announced today that Health Canada has accepted its New Drug Submission (NDS) for cenobamate tablets as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. A decision from Health Canada as to whether cenobamate tablets can be marketed and sold in Canada under this NDS is expected mid-2023. "This is an important step in our journey to address the unmet needs of adult patients diagnosed with partial-onset seizures," said Livio Di Francesco, Vice President and General Manager of Paladin. "
The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, "BHG" or "we"), the New York City-based investment advisor to clients with financial interests in Endo International Plc. ("Endo" or the "Company") (NASDAQ:ENDP),today issued an open letter to directors of the Company and its financial auditor, PricewaterhouseCoopers LLP, relating to financial disclosures.. The full open letter to the Company's directors, along with the private letters between BHG and the Company leading up to this open letter, may be found at: http://www.exposingendo.com/ Members of the Endo International Plc. Board of Directors: Mark G. Barberio, Jennifer M. Chao, Blaise Coleman, Shane
ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ:QNRX) (the "Company" or "Quoin"), a specialty pharmaceutical company focused on rare and orphan diseases, has entered into the License and Distribution Agreement and the Supply Agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ:ENDP), for the development, registration, supply, commercialization and distribution of QRX003, Quoin's lead product for Netherton Syndrome, on an exclusive basis in Canada. Under the terms of the License and Distribution Agreement, Endo Ventures has the exclusive right, which was sublicensed to its affiliate, Paladin Labs Inc., to commercialize QRX0
The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. (NASDAQ:QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada. If the product is approved, Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada. QRX003 is Quoin's lead pro
DUBLIN, July 1, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial. As Endo previously disclosed, it has been involved since 2014 in various legal proceedings filed by multiple plaintiffs, including classes of direct and indirect purchasers, which have been consolidated in the United States District Court for the Northern District of Illinois under the c
Piper Sandler downgraded Endo Intl from Neutral to Underweight and set a new price target of $1.00 from $3.00 previously
Citigroup reiterated coverage of Endo International with a rating of Buy and set a new price target of $6.00 from $11.00 previously
Piper Sandler reiterated coverage of Endo International with a rating of Neutral and set a new price target of $3.00 from $5.00 previously
Barclays downgraded Endo International from Equal-Weight to Underweight and set a new price target of $2.00 from $5.00 previously
Barclays reiterated coverage of Endo International with a rating of Equal-Weight and set a new price target of $5.00 from $7.00 previously
Piper Sandler downgraded Endo Intl from Overweight to Neutral and set a new price target of $3.00 from $10.00 previously
RBC Capital reiterated coverage of Endo International with a rating of Sector Perform and set a new price target of $5.00 from $6.00 previously
RBC Capital Mkts resumed coverage of Endo Intl with a rating of Sector Perform and set a new price target of $7.00
Morgan Stanley reiterated coverage of Endo International with a rating of Underweight and set a new price target of $7.00 from $5.00 previously
Barclays reiterated coverage of Endo International with a rating of Equal Weight and set a new price target of $7.00 from $6.00 previously
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
10-Q - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
8-K - Endo International plc (0001593034) (Filer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)
4 - Endo International plc (0001593034) (Issuer)